Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoid neoplasm in adults and remains a clinical challenge to treat. It can be subdivided into germinal center B cell-like (GCB)- and activated B cell-like (ABC)- DLBCL. At least 5 subclusters play a major role in different responses to chemo-immune-therapy.
Here we focuse on cluster 5 (C5), a subdivision of ABC-DLBCL, and the development of an in-vivo experimental platform that faithfully mimics its genomic landscape. A deep understanding of multible recurrent aberrations in this C5-subcluster, like inappropriate NFkB activation, BCL2 overexpression or aberrations in PRDM1, is necessary to evolve suitable autochtonous mouse models, which can be used as pre-clinical platforms in order to develop new, innovative therapeutic strategies and to advance the future of translational research in C5-DLBCL.